In 2,502 ILBC (5.6% of total breast cancers), ERBB2 amplification is 2.3%, ERBB2 sequence mutation is 9.2%, CDK12 amplification is 0%, and the CDK12 mutation frequency is 0.5%. Here, CDK12 is linked to breast carcinoma.